Table 1 Inhibitory effect of erlotinib derivatives on Hela cells.

From: Design, synthesis and anti-cancer activity of novel 1,2,3-triazole hybrids of erlotinib against cervical cancer via MAPK signaling pathway

Erlotinib Derivatives

% cell viability (at 10 µM)

IC50 (µM)

3a

60.44 ± 2.74***

>10

3b

80.34 ± 2.09***

>10

3c

71.35 ± 0.54***

>10

3d

83.18 ± 2.56**

>10

3e

34.51 ± 1.08***

3.59 ± 0.61

3f

57.27 ± 2.32***

>10

3g

34.38 ± 2.27***

4.31 ± 0.53

3h

10.44 ± 0.80***

1.35 ± 0.74

5a

97.93 ± 7.08

>10

5b

103.30 ± 5.08

>10

5c

98.08 ± 1.59

>10

5d

103.90 ± 6.55

>10

5e

113.90 ± 5.55

>10

5f

99.82 ± 3.25

>10

5g

85.01 ± 3.26*

>10

5h

91.55 ± 3.74

>10

Erlotinib

53.02 ± 0.51***

25.91 ± 1.35

Doxorubicin

11.95 ± 1.20***

 
  1. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the CON group.
Back to article page